{
    "nctId": "NCT00752986",
    "briefTitle": "ZACtima FASlodex Trial in Postmenopausal Advance Breast Cancer Patients Instead of ZACtima FASlodex Trial",
    "officialTitle": "A Randomized,Double-blind,Parallel-group,Multicentre,Phase II Study to Evaluate the Safety and Pharmacological Activity of the Combination of Vandetanib (100 or 300 MG/Daily or Placebo)With Fulvestrant (Loading Dose)in Postmenopausal Advanced BC Patients",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 39,
    "primaryOutcomeMeasure": "Event Free Survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Post menopausal women with locally advanced or metastatic breast cancer\n* Patients may have either measurable or non-measurable disease, as defined by RECIST criteria\n* One previous hormone therapy or one previous chemotherapy for advanced disease are allowed (patients who have stable but evident disease after chemotherapy are eligible)\n* estrogen receptor positive ER+ and/or progesterone receptor positive PR+ on primary or secondary tumour\n\nExclusion Criteria:\n\n* Hormone receptor negative tumours (ER and PR negative)\n* Presence of life-threatening metastatic visceral disease\n* Significant cardiovascular event (e.g. myocardial infarction, superior vena cava \\[SVC\\] syndrome, New York Heart Association \\[NYHA\\] classification of heart disease \u00b32) within 3 months before entry, or presence of cardiac disease that in the opinion of\n* History of arrhythmia or QTc with Bazett's correction unmeasurable or \u2265 480 msec on screening ECG",
    "sex": "FEMALE",
    "minimumAge": "45 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}